Skip to content
    Clinical Trials

    Th17-Based Model and Biomarkers Stratify Severe irAE Risk in Advanced NSCLC

    Peng et alCancer immunology, immunotherapy : CII

    Th17-Based Model and Biomarkers Stratify Severe irAE Risk in Advanced NSCLC
    In a post hoc analysis of the randomized phase III ORIENT-11 trial, investigators examined baseline tumor RNA-sequencing data from 266 patients with advanced non-small cell lung cancer (NSCLC) receiving sintilimab (an anti-PD-1 antibody) plus chemotherapy. Severe immune-related adverse events (irAEs) occurred in 19 patients (7.14%). Gene set enrichment analysis (GSEA) and pathway enrichment analyses revealed that the Th17 cell differentiation pathway was significantly enriched in patients who experienced severe irAEs.
    Using 50-time LASSO regressions based on this enriched pathway, investigators constructed a predictive model for severe irAEs that demonstrated an AUC of 0.904 in the training cohort and 0.769 in the validation cohort. Because this toxicity model acted independently of antitumor efficacy, it was integrated with established efficacy biomarkers—specifically PD-L1 expression and tumor-infiltrating lymphocytes (TIL)—to create a four-quadrant risk-benefit stratification framework.
    This integrated stratification system categorized patients into four distinct groups that showed divergent outcomes, with objective response rates ranging between 51.1% and 92.9%, severe irAE incidence ranging from 0% to 46.7%, and reported differences in progression-free survival (PFS). The authors propose that this multi-biomarker framework can assist in individualizing immunotherapy decisions beyond one-size-fits-all empirical regimens.

    Key Takeaways

    • In patients with advanced NSCLC receiving sintilimab plus chemotherapy, severe immune-related adverse events occurred in 7.14% (19/266) of individuals, with significant enrichment found in the Th17 cell differentiation pathway.
    • A predictive toxicity model derived from the Th17 pathway demonstrated an AUC of 0.904 in the training cohort and 0.769 in the validation cohort.
    • Integrating the Th17 toxicity model with PD-L1 expression and tumor-infiltrating lymphocytes stratified patients into four risk-benefit groups, with objective response rates ranging from 51.1% to 92.9% and severe adverse event rates ranging from 0% to 46.7%, alongside differences in progression-free survival.
    Read the original sourceCancer immunology, immunotherapy : CII